Panbio Nasal ELISA kit

ABBOTT’S PANBIO RAPID ANTIGEN TEST RECEIVES CE MARK FOR ASYMPTOMATIC SCREENING AND SELF-ADMINISTERED SAMPLE COLLECTION WITH NASAL SWAB
– Panbio™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic
– Frequent screening of asymptomatic and symptomatic people helps restore a sense of safety at workplaces, schools, travel and recreational settings, and other places where people gather in large numbers
– Test is approved for use with a patient-friendly and minimally invasive nasal swab; patients can self-administer sample collection under a healthcare professional’s supervision
– Panbio COVID-19 Ag delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology
– Test performance in clinical study demonstrated 93.8% sensitivity and 100.0% specificity in asymptomatic people with high viral loads
– Along with the test, Abbott will offer complementary digital solutions: the NAVICA™ mobile app to allow people to display negative results for proof of testing and Sympheos™ for surveillance management to understand epidemiological trends
– Since August 2020 to date, Abbott has shipped 200 million Panbio rapid antigen tests to 120 countries worldwide

Leave a Reply

Your email address will not be published. Required fields are marked *